ClinicalTrials.gg
CompletedNCT03573297Updated Sep 28, 2023Results posted

A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features

A Phase 3 interventional study of Cariprazine and Placebo in Bipolar I Disorder, Mania and Depression, sponsored by AbbVie. Completed at 108 sites in 11 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
901
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies in Mania with a site in United States — 5 open to participants now, 5 under way, 4 of them phase 3. Mania · United States.

Enrollment
2nd of 88
901 · median 83
Started
2018
with 1 other
Phase 3
32 of 94
4 open now
Registered
84th of 94
by date

Among the 94 studies in Mania with a site in United States, this one is the 2nd largest by enrollment of the 88 interventional ones that give a count, is one of 2 that started in 2018, is one of 32 in phase 3, and was the 84th registered.

Mania

167 studies on the registry are indexed under Mania; 14 are open to participants now.

Browse Mania studies →

Open to participants now

5 of the 94 studies in Mania with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Mania studies recruiting now, 5 (42%) set no upper age limit and 7 (58%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Mania with a site in United States, or all of them as a file.
02

Study summary

  1. To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/day compared with placebo in prevention of relapse in patients with bipolar I disorder whose current episode (i.e. index episode) is manic or depressive, with or without mixed features; 2) To evaluate the efficacy and safety of cariprazine at a target dose of 1.5 mg/day compared with placebo in prevention of relapse in patients with bipolar I disorder whose current episode (i.e. index episode) is manic or depressive, with or without mixed features who were initially stabilized on a target dose of 3.0 mg/day
03

Conditions studied

  • Bipolar I Disorder
  • Mania
  • Depression

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently meet the , Fifth Edition (DSM-5) criteria for bipolar I disorder, and at least one of the following two criteria:
  • Current episode manic, with or without mixed features, having a total Young Mania Rating Scale (YMRS) total score ≥ 20 and a score of at least 4 on 2 YMRS items (irritability, speech, content, or disruptive/aggressive behavior);
  • OR current episode depressive, with or without mixed features, having a Montgomery-Asberg Depression Rating Scale (MADRS) total score ≥ 23 and a score of at least 3 on 2 MADRS items (apparent sadness, reported sadness, inner tension or inability to feel).

Exclusion criteria

Exclusion Criteria:

  • Four or more episodes of a mood disturbance within the 12 months before Visit 1;
  • Diagnosis of another psychiatric disorder other than bipolar disorder with the exception of specific phobias.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
901 participants (actual)

Study arms

  • Experimental
    Double-Blind Cariprazine 3.0 mg/day

    Participants randomized to receive cariprazine 3.0 mg once daily (QD) for up to 39 weeks.

    Drug: Cariprazine

  • Experimental
    Double-Blind Cariprazine 1.5 mg/day

    Participants randomized to receive cariprazine 1.5 mg QD for up to 39 weeks.

    Drug: Cariprazine

  • Placebo comparator
    Double-Blind Placebo

    Participants randomized to receive placebo QD for up to 39 weeks.

    Drug: Placebo

  • Experimental
    Open Label Treatment

    Participants started on cariprazine 1.5 mg QD, with a target dose of 3.0 mg QD, for up to 16 weeks.

    Drug: Cariprazine

Interventions

  • Cariprazine capsules, oral administration, once daily

  • DrugPlacebo

    Matching placebo capsules, oral administration, once daily

06

What researchers measure

Primary outcomes

  1. Time to First Relapse of Any Mood Episode During the Double-Blind Treatment Period

    Relapse was defined as the occurrence of any 1 of the following: * Young Mania Rating Score (YMRS) total score ≥ 17 (range 0-60; higher score indicates a worse outcome); * Montgomery Asberg Depression Rating Scale; (MADRS) total score ≥ 20 (range 0-60; higher score indicates more depressive symptoms); * Clinical Global Impression-Improvement scale (CGI-S) ≥ 4 (range from 1 \[normal, not at all ill\] to 7 \[extremely ill\]); * Initiation of additional psychiatric medication; * Psychiatric hospitalization; * Exacerbation of illness as judged by clinical impression of the Investigator. Time to first relapse (days) was calculated as the date of the first relapse - the date of randomization + 1. Participants who did not meet the relapse criteria were considered censored at the time of completion or discontinuation from the Double-Blind Treatment Period (DBTP) of the study. Percentiles (95% Confidence Intervals \[CI\]) are based on Kaplan-Meier estimates.

    Time frame: From Week 16 to Week 55

07

Results

Posted Sep 28, 2023

Participant flow

Open Label Treatment Period
Participant flow — Open Label Treatment Period
MilestoneOpen Label Treatment PeriodDouble-Blind Placebo QDDouble-Blind Cariprazine 1.5 mg QDDouble-Blind Cariprazine 3.0 mg QD
Started896000
Completed440000
Not completed456000
Withdrew: Adverse event67000
Withdrew: Lack of efficacy35000
Withdrew: Withdrawal by subject104000
Withdrew: Lost to follow-up55000
Withdrew: Pregnancy1000
Withdrew: Protocol violation17000
Withdrew: Non-compliance with study drug25000
Withdrew: Study terminated by sponsor2000
Withdrew: Failure to meet randomization criteria143000
Withdrew: Other, not specified7000
Double-Blind Treatment Period
Participant flow — Double-Blind Treatment Period
MilestoneOpen Label Treatment PeriodDouble-Blind Placebo QDDouble-Blind Cariprazine 1.5 mg QDDouble-Blind Cariprazine 3.0 mg QD
Started0145147148
Randomized and treated in double-blind treatment period0145144147
Completed0798284
Not completed0666564
Withdrew: Relapse event during double-blind treatment period0292526
Withdrew: Adverse event0151
Withdrew: Lack of efficacy0100
Withdrew: Withdrawal by subject0231114
Withdrew: Lost to follow-up0449
Withdrew: Protocol violation0384
Withdrew: Non-compliance with study drug0044
Withdrew: Other, not specified0586

Outcome measures

PrimaryTime to First Relapse of Any Mood Episode During the Double-Blind Treatment Period

Relapse was defined as the occurrence of any 1 of the following: * Young Mania Rating Score (YMRS) total score ≥ 17 (range 0-60; higher score indicates a worse outcome); * Montgomery Asberg Depression Rating Scale; (MADRS) total score ≥ 20 (range 0-60; higher score indicates more depressive symptoms); * Clinical Global Impression-Improvement scale (CGI-S) ≥ 4 (range from 1 \[normal, not at all ill\] to 7 \[extremely ill\]); * Initiation of additional psychiatric medication; * Psychiatric hospitalization; * Exacerbation of illness as judged by clinical impression of the Investigator. Time to first relapse (days) was calculated as the date of the first relapse - the date of randomization + 1. Participants who did not meet the relapse criteria were considered censored at the time of completion or discontinuation from the Double-Blind Treatment Period (DBTP) of the study. Percentiles (95% Confidence Intervals \[CI\]) are based on Kaplan-Meier estimates.

Time frame:
From Week 16 to Week 55
Reported as:
Median · days
Time to First Relapse of Any Mood Episode During the Double-Blind Treatment Period
daysDouble-Blind Placebo QDDouble-Blind Cariprazine 1.5 mg QDDouble-Blind Cariprazine 3.0 mg QD
25% percentileNA (156.0 to NA)NA (220.0 to NA)NA (224.0 to NA)
50% percentileNA (NA to NA)NA (NA to NA)NA (NA to NA)
75% percentileNA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Double-Blind Placebo QD vs Double-Blind Cariprazine 1.5 mg QD · Log Rank · p = 0.5745 (P-value is based on the log-rank test stratified by modified index episode (manic or depressive) and region (US, non-US).) · Hazard ratio (hr): 0.83 · 95% CI 0.48 to 1.43Hazard ratio (Cariprazine 1.5 or 3.0 mg/day vs. Placebo) is based on Cox proportional hazards regression model, with treatment group as an explanatory variable, stratified by modified index episode (manic or depressive) and region (US, non-US).
  • Double-Blind Placebo QD vs Double-Blind Cariprazine 3.0 mg QD · Log Rank · p = 0.6308 (P-value is based on the log-rank test stratified by modified index episode (manic or depressive) and region (US, non-US).) · Hazard ratio (hr): 0.89 · 95% CI 0.52 to 1.51Hazard ratio (Cariprazine 1.5 or 3.0 mg/day vs. Placebo) is based on Cox proportional hazards regression model, with treatment group as an explanatory variable, stratified by modified index episode (manic or depressive) and region (US, non-US).

Adverse events

Collected over Open Label Treatment Period: from enrollment (all-cause mortality [ACM]) or first dose of study drug (adverse events [AEs]) through Week 16 (Day113). Double-Blind Treatment Period (ACM/AEs): From first dose of double-blind treatment up to end of study, Week 59 (Day 414).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open Label Treatment Period1/901 (0.1%)19/896 (2.1%)256/896 (28.6%)
Double-Blind Placebo QD1/145 (0.7%)5/145 (3.4%)27/145 (18.6%)
Double-Blind Cariprazine 1.5 mg QD0/147 (0%)7/144 (4.9%)34/144 (23.6%)
Double-Blind Cariprazine 3.0 mg QD0/148 (0%)3/147 (2%)34/147 (23.1%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventOpen Label Treatment PeriodDouble-Blind Placebo QDDouble-Blind Cariprazine 1.5 mg QDDouble-Blind Cariprazine 3.0 mg QD
BIPOLAR I DISORDERPsychiatric disorders0/8962/1451/1441/147
APPENDICEAL ABSCESSInfections and infestations0/8960/1451/1440/147
APPENDICITIS PERFORATEDInfections and infestations0/8960/1451/1440/147
CORONAVIRUS PNEUMONIAInfections and infestations0/8960/1451/1440/147
SACRAL RADICULOPATHYNervous system disorders0/8960/1451/1440/147
BIPOLAR DISORDERPsychiatric disorders3/8960/1451/1441/147
MAJOR DEPRESSIONPsychiatric disorders0/8960/1451/1440/147
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders0/8960/1451/1440/147
FALLInjury, poisoning and procedural complications0/8961/1450/1440/147
OVERDOSEInjury, poisoning and procedural complications0/8961/1450/1440/147
Most frequent other events
Most frequent other events
EventOpen Label Treatment PeriodDouble-Blind Placebo QDDouble-Blind Cariprazine 1.5 mg QDDouble-Blind Cariprazine 3.0 mg QD
AKATHISIANervous system disorders105/8962/1456/1442/147
HEADACHENervous system disorders79/89615/14514/14410/147
WEIGHT INCREASEDInvestigations40/8967/14511/14413/147
INSOMNIAPsychiatric disorders77/8965/1459/1446/147
NAUSEAGastrointestinal disorders62/8961/1452/1440/147
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations8/8964/1453/14410/147

Baseline characteristics

Safety Population: all participants who received at least 1 dose of study medication.

Age, Customized
Age, Customized(Participants)Open Label Treatment Period
< 45 years539
≥ 45 years357
Sex: Female, Male
Sex: Female, Male(Participants)Open Label Treatment Period
Female542
Male354
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Open Label Treatment Period
Hispanic or Latino89
Not Hispanic or Latino806
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Open Label Treatment Period
American Indian or Alaska Native3
Asian32
Native Hawaiian or Other Pacific Islander2
Black or African American258
White591
More than one race10
Unknown or Not Reported0
08

Study locations

108 sites
  • Woodland International Research Group /ID# 232932
    Little Rock, Arkansas 72211, United States
  • Woodland Research Northwest, LLC /ID# 232982
    Rogers, Arkansas 72758-6442, United States
  • California Pharmaceutical Research Institute Inc. /ID# 232745
    Anaheim, California 92804, United States
  • Advanced Research Center /ID# 233120
    Anaheim, California 92805, United States
  • CI Trials /ID# 232642
    Bellflower, California 90706-7079, United States
  • Synexus Clinical Research US Inc. /ID# 232743
    Cerritos, California 90703, United States
  • ATP Clinical Research, Inc /ID# 232979
    Costa Mesa, California 92626-4607, United States
  • ProScience Research Group /ID# 232945
    Culver City, California 90230-6632, United States
  • Collaborative Neuroscience Research - Orange County /ID# 233077
    Garden Grove, California 92845, United States
  • Behavioral Research Specialists, LLC /ID# 232980
    Glendale, California 91206-4261, United States
  • Omega Clinical Trials LLC /ID# 233150
    La Habra, California 90631-3842, United States
  • Synergy San Diego /ID# 232740
    Lemon Grove, California 91945-2956, United States
  • Alliance for Research - Long Beach /ID# 232926
    Long Beach, California 90807, United States
  • NRC Research Institute /ID# 232741
    Orange, California 92868, United States
  • CNRI-San Diego /ID# 232748
    San Diego, California 92102, United States
  • Artemis Institute for Clinical Research /ID# 233151
    San Marcos, California 92078-2338, United States
  • Artemis Institute for Clinical Research /ID# 233152
    San Marcos, California 92078-2338, United States
  • Collaborative Neuroscience Research LLC /ID# 232750
    Torrance, California 90502, United States
  • Duplicate_MCB Clinical Research Centers LLC /ID# 232838
    Colorado Springs, Colorado 80910, United States
  • Velocity Clinical Research - Hallandale Beach /ID# 232647
    Hallandale Beach, Florida 33009-4427, United States
  • Research Centers of America - Hollywood FL /ID# 232649
    Hollywood, Florida 33024-2706, United States
  • CNS Healthcare - Jacksonville /ID# 233160
    Jacksonville, Florida 32256-6039, United States
  • Meridien Research /ID# 232941
    Maitland, Florida 32751, United States
  • Miami Lakes Medical Research /ID# 232826
    Miami Lakes, Florida 33016, United States
  • University of South Florida /ID# 233093
    Tampa, Florida 33612, United States
  • Synexus Clinical Research, Inc /ID# 232950
    Atlanta, Georgia 30328, United States
  • Atlanta Center for Medical Research /ID# 232832
    Atlanta, Georgia 30331, United States
  • CenExcel iResearch LLC /ID# 233045
    Decatur, Georgia 30030, United States
  • Atlanta Behavioral Research, LLC /ID# 232935
    Dunwoody, Georgia 30338, United States
  • NeuroPsychiatric Research Practice & Associate LTD /ID# 232840
    Winfield, Illinois 60190, United States
  • Louisiana Clinical Research /ID# 232685
    Shreveport, Louisiana 71101, United States
  • CBH Health LLC /ID# 232699
    Gaithersburg, Maryland 20877, United States
  • St. Charles Psychiatric Associates - Midwest Research Group /ID# 232709
    Saint Charles, Missouri 63304, United States
  • Duplicate_Altea Research Institute /ID# 232784
    Las Vegas, Nevada 89102, United States
  • Hassman Research Institute /ID# 233088
    Berlin, New Jersey 08009, United States
  • Neurobehavioral Research Inc /ID# 232791
    Cedarhurst, New York 11516, United States
  • New Hope Clinical Research Inc. /ID# 232716
    Charlotte, North Carolina 28211, United States
  • Richard Weisler MD, PA & Assoc /ID# 233049
    Raleigh, North Carolina 27609, United States
  • Clinical Inquest Center Ltd /ID# 233043
    Beavercreek, Ohio 45431-2573, United States
  • DUPLICATE_The Ohios State University Department of Psychiatry /ID# 232739
    Columbus, Ohio 43210, United States
  • Midwest Clinical Research Center /ID# 232737
    Dayton, Ohio 45417, United States
  • Sooner Clinical Research /ID# 232931
    Oklahoma City, Oklahoma 73112, United States
  • Community Clinical Research Inc. /ID# 232672
    Austin, Texas 78754, United States
  • Pillar Clinical Research LLC /ID# 232667
    Richardson, Texas 75080, United States
  • Pillar Clinical Research LLC /ID# 232673
    Richardson, Texas 75080, United States
  • Family Psychiatry of The Woodlands /ID# 232943
    The Woodlands, Texas 77381, United States
  • Mental Health Centre - Prof.Dr.Ivan Temkov-Burgas /ID# 232777
    Burgas, 8001, Bulgaria
  • State Psychiatry Hospital-Kardzhali; Third Male Department /ID# 232779
    Kardzhali, 6600, Bulgaria
  • MHAT Dr. Hristo Stambolski EOOD; Hospital Pharmacy /ID# 232893
    Kazanlak, 6100, Bulgaria
  • State Psychiatric Hospital - Lovech /ID# 232771
    Lovech, 5500, Bulgaria
  • Second Psychiatric Clinic for General Psychiatry and Addictions of UMHAT Dr. Geo /ID# 232773
    Pleven, 5800, Bulgaria
  • UMHAT Dr Georgi Stranski EAD /ID# 233105
    Pleven, 5800, Bulgaria
  • UMHAT Kanev /ID# 233101
    Ruse, 7002, Bulgaria
  • Clinic of Child Psychiatry St Nicolas /ID# 232925
    Sofia, 1431, Bulgaria
  • MHAT Targovishte /ID# 232942
    Targovishte, 7700, Bulgaria
  • Inje University Busan Paik Hospital /ID# 233097
    Busan, 47392, Korea, Republic of
  • Inje University Haeundae Hospital /ID# 233141
    Busan, 48108, Korea, Republic of
  • Chonnam National University Hospital /ID# 233098
    Gwangju, 61469, Korea, Republic of
  • Jeju National University Hospital /ID# 233104
    Jeju, 63238, Korea, Republic of
  • Duplicate_Chonbuk National University Hospital /ID# 232654
    Jeonju, 54907, Korea, Republic of
  • Hospital Raja Permaisuri Bainun /ID# 233114
    Ipoh, Perak 30450, Malaysia
  • University Malaya Med Ctr /ID# 233108
    Kuala Lumpur, 59100, Malaysia
  • Specjalistyczny Gabinet Lekarski /ID# 232702
    Lublin, Lubelskie 20-582, Poland
  • Centrum Badan Klinicznych PI-House sp. z o.o. /ID# 232848
    Gdansk, Pomorskie 80-546, Poland
  • Indywidualna Specjalistyczna Praktyka Lekarska Filip Rybakowski /ID# 233170
    Poznan, Slaskie 60-744, Poland
  • Poradnia Zdrowia Psychicznego /ID# 232878
    Chelmno, 86-200, Poland
  • INSPIRA Clinical Research /ID# 232704
    San Juan, 00918, Puerto Rico
  • Kazan State Medical University /ID# 233110
    Kazan, Tatarstan, Respublika 420012, Russian Federation
  • Mental Health Research Centre /ID# 232864
    Moscow, 115522, Russian Federation
  • Clinical Psychiatry Hospital #1 of Nizhniy Novgorod /ID# 232946
    Nizhny Novgorod, 603155, Russian Federation
  • Orenburg Regional Clinical Psychiatric Hospital #1 /ID# 232933
    Orenburg, 460006, Russian Federation
  • State Public Institution of Healthcare Leningrad Regional Psychoneurology Dispen /ID# 232872
    Roschino, 188820, Russian Federation
  • I. I. Skvortsov-Stepanov Psychiatric Hospital #3 /ID# 232930
    Saint Petersburg, 197341, Russian Federation
  • St. Nicolas Psychiatric Hospital /ID# 232858
    Saint-Petersburg, 190121, Russian Federation
  • St. Nicolas Psychiatric Hospital /ID# 232859
    Saint-Petersburg, 190121, Russian Federation
  • Saratov City Clinical Hospital #2 n.a. V. I. Razumovsky /ID# 232936
    Saratov, 410028, Russian Federation
  • Regional Clinical Psychiatry Hospital /ID# 232856
    Saratov, 410060, Russian Federation
  • National Medical Research Center of Psychiatry and Neurology n.a. V.M. Bekhterev /ID# 232927
    St. Petersburg, 192019, Russian Federation
  • National Medical Research Center of Psychiatry and Neurology n.a. V.M. Bekhterev /ID# 232928
    St. Petersburg, 192019, Russian Federation
  • Ltd Clinic Hundred Years /ID# 232866
    Tomsk, 634009, Russian Federation
  • Region Specialized Psychiatric Hospital #2 /ID# 232850
    Tonnelniy, 357034, Russian Federation
  • University Clinical Center Serbia /ID# 233095
    Belgrade, Beograd 11000, Serbia
  • University Clinical Center Kragujevac /ID# 233096
    Kragujevac, Sumadijski Okrug 34000, Serbia
  • Clinical Center Vojvodina /ID# 233038
    Novi Sad, Vojvodina 21000, Serbia
  • Clinical Hospital Center Dr Dragisa Misovic - Dedinje /ID# 232641
    Belgrade, 11040, Serbia
  • Institute of Mental Health /ID# 232958
    Belgrade, 11108, Serbia
  • Special Hospital for Psychiatric Diseases Kovin /ID# 232829
    Kovin, 26220, Serbia
  • Clinical Centre Kragujevac /ID# 232874
    Kragujevac, 34000, Serbia
  • Specialized Hospital for Neuropsychiatric Diseases Sveti Vracevi /ID# 232846
    Novi Knezevac, 23330, Serbia
  • Taipei Veterans General Hospital /ID# 232947
    Taipei City, Taipei 11217, Taiwan
  • Taipei Tzu Chi Hospital /ID# 233128
    New Taipei, 23142, Taiwan
  • China Medical University Hospital /ID# 233091
    Taichung City, 40447, Taiwan
  • National Cheng Kung University Hospital /ID# 233109
    Tainan, 704, Taiwan
  • Tri-Service General Hospital /ID# 233078
    Taipei City, 11490, Taiwan
  • Maharaj Nakorn Chiang Mai Hospital /ID# 232860
    Chiang Mai, 50200, Thailand
  • Suan Prung Psychiatric Hospital /ID# 232862
    Muang, 50100, Thailand
  • Cherkasy regional psychiatric hospital of the CRC /ID# 232686
    Smila, Cherkaska Oblast 20708, Ukraine
  • Geikivka multidisciplinary hospital for psychiatric care /ID# 232678
    Kryvbas Village, Dnipropetrovska Oblast 53054, Ukraine
  • SI Institution Neurology Psychiatry and Narcology NAMS of Ukraine /ID# 232937
    Kharkiv, Kharkivska Oblast 61068, Ukraine
  • SI Institution Neurology Psychiatry and Narcology NAMS of Ukraine /ID# 232938
    Kharkiv, Kharkivska Oblast 61068, Ukraine

Showing the first 100 of 108 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Sep 2022, 50 months.

Results were first posted in Sep 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2018
First posted
Jun 29, 2018
StartActual
Jun 15, 2018
Primary completionActual
Sep 5, 2022
CompletionActual
Sep 5, 2022
Results first posted
Sep 28, 2023
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03573297
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 29, 2018
Start date
Jun 15, 2018
Primary completion
Sep 5, 2022
Completion
Sep 5, 2022
Results posted
Sep 28, 2023
Last update
Sep 28, 2023

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion